Trials / Terminated
TerminatedNCT00226785
Dexmedetomidine for Continuous Sedation
A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of Intravenous Dexmedetomidine With Propofol/Midazolam for Continuous Sedation (24 Hours to 14 Days) of Ventilated Patients in Intensive Care Unit
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 900 (planned)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of sedation in long-stay intensive care unit (ICU) patients, and that dexmedetomidine, compared with current best practice, reduces the length of ICU stay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine |
Timeline
- Start date
- 2005-10-01
- Completion
- 2006-07-01
- First posted
- 2005-09-27
- Last updated
- 2006-11-14
Locations
4 sites across 2 countries: Finland, Switzerland
Source: ClinicalTrials.gov record NCT00226785. Inclusion in this directory is not an endorsement.